FIELD: biotechnology.
SUBSTANCE: present group of inventions refers to immunology. What is presented is an anti-protein-1 antibody programmed cell death (PD-1) or its antigen-binding fragment, as well as a coding nucleic acid, a vector containing said nucleic acid, an isolated cell transformed with said vector, a method of producing said antibody or its antigen-binding fragment and a composition thereof for preventing or treating cancer.
EFFECT: antibody according to the invention is able to bind to PD-1 and inhibit its activity, therefore it is applicable for development of immunotherapeutic agents against various diseases associated with PD-1.
11 cl, 23 dwg, 16 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| FUSED PROTEIN CONTAINING A VERSION OF CCL3, AND USE THEREOF | 2017 |
|
RU2727715C2 |
| ANTIBODY AGAINST TIE-2 AND ITS USE | 2020 |
|
RU2795455C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2023 |
|
RU2802944C1 |
| THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
